유럽의 합성 호르몬 시장 : 제품 유형별, 투여 경로별, 용도별, 최종 사용자별 국가별 분석 및 예측(2023-2033년)

Introduction to Europe Synthetic Hormones Market

The Europe synthetic hormones market size was estimated at $4.90 billion in 2023 and is expected to reach $10.53 billion by 2033, growing at a CAGR of 7.94% during the forecast period 2023-2033. The synthetic hormones market is advancing due to significant developments anticipated from key market players focused on creating innovative synthetic hormones.

Market Introduction

The Europe synthetic hormones market is characterized by robust research and development activities aimed at advancing medical treatments and therapies. Key pharmaceutical companies across the region are actively engaged in developing and commercializing innovative synthetic hormones to address various medical conditions. This market is driven by increasing healthcare expenditure, rising prevalence of hormonal disorders such as thyroid dysfunction and hormone-related cancers, and growing awareness among healthcare professionals and patients about advanced treatment options. Regulatory support and stringent quality standards further bolster market growth by ensuring the safety and efficacy of synthetic hormone products. With ongoing advancements in biotechnology and pharmaceutical sciences, Europe continues to be a significant hub for the development and adoption of cutting-edge synthetic hormone therapies, contributing to improved patient outcomes and healthcare advancements across the continent.

Market Segmentation:

Segmentation 1: by Product Type

• Steroid Hormones
• Peptide Hormones
• Others

Segmentation 2: by Route of Administration

• Subcutaneous
• Oral
• Intravenous/Intramuscular
• Others

Segmentation 3: by Application

• Diabetes
• Growth Hormone Deficiency
• Contraception
• Male Hypogonadism
• Menopause
• Others

Segmentation 4: by End User

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Segmentation 5: by Country

• U.K.
• Germany
• France
• Italy
• Spain
• Rest-of-Europe

How can this report add value to an organization?

Workflow/Innovation Strategy: The Europe synthetic hormones market (by product type) has been segmented based on product type, including peptide hormones, steroid hormones, and others. Moreover, the study provides the reader with a detailed understanding of the different routes of administration and application.

Growth/Marketing Strategy: To foster growth in the synthetic hormones market, a dual strategy focusing on research and development for safer, more effective formulations, alongside expanding outreach through strategic partnerships and education campaigns, is essential. Emphasizing personalized medicine and leveraging digital platforms for market expansion and patient engagement can also be pivotal in driving market growth and visibility.

Competitive Strategy: Key players in the Europe synthetic hormones market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the synthetic hormones market has been done to help the reader understand how players stack against each other, presenting a clear market landscape.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some prominent names in the market include:

• Ferring B.V.
• Novo Nordisk A/S
• Ipsen Pharma
• Novartis AG
• Perrigo Company plc
• Sanofi

Table of Contents

Executive Summary

Scope and Definition

1 Markets

• 1.1 Trends: Current and Future Impact Assessment
  • 1.1.1 Trend 1: Personalized Synthetic Hormones Therapies
  • 1.1.2 Trend 2: Integration of Artificial Intelligence (AI)
• 1.2 Market Footprint and Growth Potential, $Billion, 2022-2033
• 1.3 Research and Development Review
  • 1.3.1 Patent Publishing Trend (by Country)
  • 1.3.2 Patent Publishing Trend (by Year)
• 1.4 Regulatory Landscape
• 1.5 Market Dynamics: Overview
  • 1.5.1 Market Drivers
  • 1.5.2 Market Restraints
  • 1.5.3 Market Opportunities

2 Regions

• 2.1 Regional Summary
• 2.2 Drivers and Restraints
• 2.3 Europe
  • 2.3.1 Driving Factors for Market Growth
  • 2.3.2 Factors Challenging the Market
  • 2.3.3 U.K.
  • 2.3.4 Germany
  • 2.3.5 France
  • 2.3.6 Italy
  • 2.3.7 Spain
  • 2.3.8 Rest-of-Europe

3 Markets - Competitive Benchmarking & Company Profiles

• 3.1 Company Assessment
  • 3.1.1 Ferring B.V.
    • 3.1.1.1 Overview
    • 3.1.1.2 Top Products
    • 3.1.1.3 Top Competitors
    • 3.1.1.4 Key Personnel
    • 3.1.1.5 Analyst View
  • 3.1.2 Novo Nordisk A/S
    • 3.1.2.1 Overview
    • 3.1.2.2 Top Products
    • 3.1.2.3 Top Competitors
    • 3.1.2.4 Key Personnel
    • 3.1.2.5 Analyst View
  • 3.1.3 Ipsen Pharma
    • 3.1.3.1 Overview
    • 3.1.3.2 Top Products
    • 3.1.3.3 Top Competitors
    • 3.1.3.4 Key Personnel
    • 3.1.3.5 Analyst View
  • 3.1.4 Novartis AG
    • 3.1.4.1 Overview
    • 3.1.4.2 Top Products
    • 3.1.4.3 Top Competitors
    • 3.1.4.4 Key Personnel
    • 3.1.4.5 Analyst View
  • 3.1.5 Perrigo Company plc
    • 3.1.5.1 Overview
    • 3.1.5.2 Top Products
    • 3.1.5.3 Top Competitors
    • 3.1.5.4 Key Personnel
    • 3.1.5.5 Analyst View
  • 3.1.6 Sanofi
    • 3.1.6.1 Overview
    • 3.1.6.2 Top Products
    • 3.1.6.3 Top Competitors
    • 3.1.6.4 Key Personnel
    • 3.1.6.5 Analyst View

4 Research Methodology

• 4.1 Data Sources
  • 4.1.1 Primary Data Sources
  • 4.1.2 Secondary Data Sources
  • 4.1.3 Data Triangulation